Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign

The campaign places renewed focus on a disease that remains incurable despite major scientific advances

Everest Medicines expands Asia-Pacific presence with licensing deal for Bejescin

Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio

Cancer drug “iza-bren” posts strong Phase 3 wins across multiple tumor types

The companies say the drug has now demonstrated clinical benefit in three separate Phase 3 trials

Moderna and Merck’s mRNA cancer vax combo shows 5-year survival in melanoma trial

An exploratory overall survival signal also leaned in favor of the combination, though the companies noted the result remains preliminary

BioNTech and Bristol Myers Squibb drug shows strong early signal in lung cancer trial

The safety profile was described as manageable, though not without notable toxicities

Bristol Myers Squibb wins EU approval for Opdivo-based frontline treatment in advanced hodgkin lymphoma

The approval is supported by results from the Phase 3 SWOG 1826 trial

AstraZeneca's India revenue climbs 33% YoY to Rs. 22.76 billion in FY26

While oncology contributed Rs. 16,100.9 million to remain company's largest therapy area, the key highlight was receipt of 11 new regulatory approvals for medicines and indications

Pfizer and Innovent Biologics strike $10 billion cancer drug deal

This alliance, covering up to 12 antibody drugs, highlights the growing trend of large-scale collaborations between Chinese biotech firms and global pharmaceutical giants

Glenmark posts strong FY26 results with 27.5% revenue jump

Eli lilly goes all-in on vaccines with $3b+ triple acquisition push into infectious disease prevention

Lilly will acquire Curevo in a deal worth up to $1.5 billion in cash, including upfront and milestone-based payments.